Search

Your search keyword '"Gerber, David E."' showing total 432 results

Search Constraints

Start Over You searched for: Author "Gerber, David E." Remove constraint Author: "Gerber, David E." Search Limiters Full Text Remove constraint Search Limiters: Full Text
432 results on '"Gerber, David E."'

Search Results

2. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

6. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

7. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice

9. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non–Small-Cell Lung Cancer (RTOG 3505)

10. TTFields (Tumor Treating Fields) associés au traitement standard dans les cancers du poumon non à petites cellules métastatiques en progression après sels de platine :Étude internationale, randomisée de phase 3 LUNAR

12. Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.

13. Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

15. Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.

17. T-cell tolerant fraction as a predictor of immune-related adverse events

18. Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors

22. Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis

23. PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients

24. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

25. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

26. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

30. Survival of cancer survivors with a new pancreatic cancer diagnosis

31. Oncologic emergencies and urgencies: A comprehensive review

32. Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

34. Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy

38. Association between immune-related adverse event timing and treatment outcomes

39. Humoral and cellular correlates of a novel immune-related adverse event and its treatment

40. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

41. Survival of cancer survivors with a new pancreatic cancer diagnosis.

Catalog

Books, media, physical & digital resources